Omeros stock rises after a $340 million deal with Novo Nordisk. Learn about its improved risk profile and covered call trade ...

Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906).

(RTTNews) - Omeros Corp. (OMER), a clinical-stage biopharmaceutical company focused on complement-mediated diseases, oncology, and addictive disorders, today announced its financial results for the ...

Researchers describe pegcetacoplan, a new class of medication, as the “closest thing to a cure” for the rare, severe kidney disease C3 glomerulopathy.

As an undergraduate, University of Cincinnati fourth-year medical student Shalini Roy double-majored in biomolecular sciences and film. Opportunities to combine her interests had been rare — but if ...

A new study has discovered a molecular signal that tumors exploit to exhaust the T cells meant to destroy them-and how silencing that signal could revive the body's immunity. The study led by Weill ...